HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm

Join us for this dynamic Webinar on the latest therapeutic strategies for HER2-positive early and metastatic breast cancer! Engage with the experts as they discuss challenging cases highlighting systemic therapy options and toxicity management in HER2-positive early breast cancer, along with optimal therapy sequencing in HER2-positive metastatic breast cancer. Then, learn about emerging therapeutic strategies targeting HER2 across multiple settings. Register today!

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that each Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Agenda

  • Welcome and Introduction (5 min)
  • Case Discussion: Systemic Therapy Options for HER2-Positive EBC (25 min)
  • Case Discussion: Evolving Therapeutic Strategies for HER2-Positive MBC (25 min)
  • New Therapeutic Strategies on the Horizon for HER2-Positive Breast Cancer (25 min)
  • Summary, Final Thoughts, and Audience Question and Answer Session (10 min)

Events

Date / Time
Event Details

Faculty

Faculty
Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Faculty
Lee Schwartzberg, MD, FACP

Medical Director
West Cancer Center and Research Institute
Professor of Medicine
University of Tennessee
Health Science Center
Memphis, Tennessee

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate HER2-targeted agents into the treatment of patients with breast cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan optimal adjuvant and/or extended adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
  • Apply the latest clinical evidence on HER2-targeted agents to treat patients with HER2 low expressing tumors
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and CNS metastases
  • Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.